Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
81 hedge funds and large institutions have $28.9M invested in Eiger BioPharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 26 closing their positions.
531% more call options, than puts
Call options by funds: $303K | Put options by funds: $48K
22% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 23
12% less funds holding
Funds holding: 92 → 81 (-11)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
87% less capital invested
Capital invested by funds: $227M → $28.9M (-$198M)
100% less funds holding in top 10
Funds holding in top 10: 6 → 0 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$4.36M |
| 2 |
Millennium Management
New York
|
+$3.07M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.96M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.94M |
| 5 |
Morgan Stanley
New York
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$10.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.24M |
| 3 |
6CM
683 Capital Management
New York
|
-$4.86M |
| 4 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$4.22M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$4.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$115K | -511 | Closed |
|
|
FRM
102
Fox Run Management
Greenwich,
Connecticut
| – | -$93K | -412 | Closed |
|
|
DTL
103
Dynamic Technology Lab
Singapore
| – | -$81K | -358 | Closed |
|
|
CM
104
Caption Management
Oklahoma City,
Oklahoma
| – | -$39K | -325 | Closed |
|
|
MLICM
105
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$17.5K | -78 | Closed |
|
|
AIM
106
Axiom Investment Management
New York
| – | -$8K | -33 | Closed |
|
EIGR Hedge Fund Activity: Q4 2022 in Review
81 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2022, worth a combined $28.9M — down 87% from $227M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of EIGR and 17 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 28 added.
The largest buyer was Barclays, adding an estimated $4.36M. The largest seller was Ameriprise, cutting an estimated $10.5M.
- 81 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2022, down from 92 in Q3 2022.
- Funds reported $28.9M of Eiger BioPharmaceuticals, Inc. stock for Q4 2022, down 87% quarter-over-quarter.
- 17 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2022 and 26 closed out, a net change of -9 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2022 was Barclays, an estimated $4.36M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2022 was Ameriprise, an estimated $10.5M sold.
Based on aggregated 13F filings for Q4 2022.